Genetically-modified human pluripotent stem cells: New hopes for the understanding and the treatment of neurological diseases?

Current Gene Therapy

Volumn 13, Issue 2, 2013, Pages 111-119

  Nedelec, Stéphane ^a   Onteniente, Brigitte ^a   Peschanski, Marc ^a   Martinat, Cécile ^a  

^a I Stem   (France)

Author keywords

Disease modeling; Drug screening; Genetic diseases; Human embryonic stem cells; Human induced pluripotent stem cells

Indexed keywords

CASPASE 3; CHOLINE ACETYLTRANSFERASE; COPPER ZINC SUPEROXIDE DISMUTASE; METHYL CPG BINDING PROTEIN 2; SOMATOMEDIN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL DIFFERENTIATION; CELL MIGRATION; DEATH; DISEASE SEVERITY; DNA MODIFICATION; DRUG SCREENING; DYSAUTONOMIA; EMBRYONIC STEM CELL; ENVIRONMENTAL FACTOR; FRAGILE X SYNDROME; GENE MUTATION; GENETIC DISORDER; GENETIC MANIPULATION; HUMAN; HUMAN GENOME; HUNTINGTON CHOREA; MYOTONIC DYSTROPHY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; PROGERIA; PROTEIN EXPRESSION; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; SKIN FIBROBLAST; WNT SIGNALING PATHWAY;

CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NERVOUS SYSTEM DISEASES; NEURONS;

EID: 84876726291     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313020005     Document Type: Review

References (112)

1. Celanire S, Campo B. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. Expert Opin Drug Discov 2012; 7(3): 261-280.
2. Zhang Y, Friedlander RM. Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther 2011; 18(12): 1139-1149.
3. Bebee TW, Dominguez CE, Chandler DS. Mouse models of SMA: tools for disease characterization and therapeutic development. Hum Genet 2012; 131(8): 1277-1293.
4. Gordon PH, Meininger V. How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol 2011; 7(11): 650-654.
5. Li XJ, Li S. Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. J Genet Genomics 2012; 39(6): 239-245.
6. Tsao W, Jeong YH, Lin S, et al. Rodent models of TDP-43: recent advances. Brain Res 2012; 1462: 26-39.
7. Edgin JO, Mason GM, Spano G, Fernandez A, Nadel L. Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment. Prog Brain Res 2012; 197: 123-151.
8. Lanson NA, Jr., Pandey UB. FUS-related proteinopathies: lessons from animal models. Brain Res 2012; 1462: 44-60.
9. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-1147.
10. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
11. Eiges R, Urbach A, Malcov M, et al. Developmental Study of Fragile X Syndrome Using Human Embryonic Stem Cells Derived from Preimplantation Genetically Diagnosed Embryos. Cell Stem Cell 2007; 1(5): 568-577.
12. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65(5): 905-914.
13. Feng Y, Zhang F, Lokey LK, et al. Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995; 268(5211): 731-734.
14. Bradley CK, Scott HA, Chami O, et al. Derivation of Huntington's disease-affected human embryonic stem cell lines. Stem Cells Dev 2011;20(3):495-502.
15. Niclis J, Trounson AO, Dottori M, et al. Human embryonic stem cell models of Huntington disease. Reprod Biomed Online 2009; 19(1): 106-113.
16. Seriola A, Spits C, Simard JP, et al. Huntington's and myotonic dystrophy hESCs: down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. Hum Mol Genet 2011; 20(1): 176-185.
17. Feyeux M, Bourgois-Rocha F, Redfern A, et al. Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Hum Mol Genet 2012; 21(17): 3883-3895.
18. Marteyn A, Maury Y, Gauthier MM, et al. Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy. Cell Stem Cell 2011; 8(4): 434-444.
19. Harper PS. Myotonic Dystrophy. 2001; 37(3rd Ed.) (London, W. B Saunders).
20. Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008; 5(4): 592-600.
21. Mankodi A, Urbinati CR, Yuan QP, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10(19): 2165-2170.
22. Timchenko NA, Iakova P, Cai ZJ, Smith JR, Timchenko LT. Molecular basis for impaired muscle differentiation in myotonic dystrophy. Mol Cell Biol 2001; 21(20): 6927-6938.
23. Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 2004; 303(5656): 383-387.
24. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004; 13(24): 3079-3088.
25. Aruga J, Mikoshiba K. Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. Mol Cell Neurosci 2003; 24(1): 117-129.
26. Aruga J, Yokota N, Mikoshiba K. Human SLITRK family genes: genomic organization and expression profiling in normal brain and brain tumor tissue. Gene 2003; 315: 87-94.
27. Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180(1-2): 7-14.
28. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008; 3(6): 649-657.
29. Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008; 3(6): 637-648.
30. Hedlund E, Isacson O. ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008; 3(6): 575-576.
31. Mateizel I, De Temmerman N, Ullmann U, et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 2006; 21(2): 503-511.
32. Mateizel I, Spits C, De Rycke M, Liebaers I, Sermon K. Derivation, culture, and characterization of VUB hESC lines. In vitro Cell Dev Biol Anim 2010; 46(3-4): 300-308.
33. Tropel P, Tournois J, Come J, et al. High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis. In vitro Cell Dev Biol Anim 2010; 46(3-4): 376-385.
34. Urbach A, Schuldiner M, Benvenisty N. Modeling for Lesch- Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 2004; 22(4): 635-641.
35. Colman A, Dreesen O. Pluripotent stem cells and disease modeling. Cell Stem Cell 2009; 5(3): 244-247.
36. Ben-David U, Kopper O, Benvenisty N. Expanding the boundaries of embryonic stem cells. Cell Stem Cell 2012; 10(6): 666-677.
37. Zacharias DG, Nelson TJ, Mueller PS, Hook CC. The science and ethics of induced pluripotency: what will become of embryonic stem cells? Mayo Clin Proc 2011; 86(7): 634-640.
38. Park IH, Arora N, Huo H, et al. Disease-Specific Induced Pluripotent Stem Cells. Cell 2008; 134(5): 877-886.
39. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
40. Lowry WE, Richter L, Yachechko R, Pet al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008; 105(8): 2883-2888.
41. Ebert AD, Yu J, Rose FF, Jr., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457(7227): 277-280.
42. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009; 461(7262): 402-406.
43. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143(4): 527-539.
44. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473(7346): 221-225.
45. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321(5893): 1218-1221.
46. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10(8): 597-609.
47. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80(1): 155-165.
48. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999; 96(11): 6307-6311.
49. Monani UR, Sendtner M, Coovert DD, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000; 9(3): 333-339.
50. McAndrew PE, Parsons DW, Simard LR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 1997; 60(6): 1411-1422.
51. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time light Cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70(2): 358-368.
52. Schrank B, Gotz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 1997; 94(18): 9920-9925.
53. Zanoteli E, Maximino JR, Conti Reed U, Chadi G. Spinal muscular atrophy: from animal model to clinical trial. Funct Neurol 2010; 25(2): 73-79.
54. Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24(1): 66-70.
55. Le TT, Pham LT, Butchbach ME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005; 14(6): 845-857.
56. Sareen D, Ebert AD, Heins BM, McGivern JV, Ornelas L, Svendsen CN. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One 2012; 7(6): e39113.
57. Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 2001; 68(3): 753-758.
58. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23(2): 185-188.
59. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008; 320(5880): 1224-1229.
60. Yasui DH, Peddada S, Bieda MC, et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci U S A 2007; 104(49): 19416-19421.
61. Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol 2005; 20(9): 747-753.
62. Schule B, Armstrong DD, Vogel H, Oviedo A, Francke U. Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure. Clin Genet 2008; 74(2): 116-126.
63. Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A 2009; 106(6): 2029-2034.
64. Cheung AY, Horvath LM, Grafodatskaya D, et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet 2011; 20(11): 2103-2115.
65. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci U S A 2011; 108(34): 14169-14174.
66. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011; 91(4): 1161-1218.
67. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2012; 10(12): 1108-1118.
68. Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. J Neurosci 2011; 31(16): 5970-5976.
69. Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2012; 8(3): 267-280.
70. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006; 140(23): 2603-2624.
71. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300(5628): 2055.
72. Varga R, Eriksson M, Erdos MR, et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2006; 103(9): 3250-3255.
73. Lammerding J, Fong LG, Ji JY, et al. Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem 2006; 281(35): 25768-25780.
74. Goldman RD, Shumaker DK, Erdos MR, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2004; 101(24): 8963-8968.
75. Columbaro M, Capanni C, Mattioli E, et al. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cell Mol Life Sci 2005; 62(22): 2669-2678.
76. Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci 2006; 119(Pt 22): 4644-4649.
77. Liu B, Zhou Z. Lamin A/C, laminopathies and premature ageing. Histol Histopathol 2008; 23(6): 747-763.
78. Navarro CL, Cau P, Levy N. Molecular bases of progeroid syndromes. Hum Mol Genet 2006; 15 Spec No 2: R151-R161.
79. Paradisi M, McClintock D, Boguslavsky RL, Pedicelli C, Worman HJ, Djabali K. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress. BMC Cell Biol 2005; 6:27.
80. Scaffidi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008; 10(4): 452-459.
81. Osorio FG, Obaya AJ, Lopez-Otin C, Freije JM. Accelerated ageing: from mechanism to therapy through animal models. Transgenic Res 2009; 18(1): 7-15.
82. Zhang J, Lian Q, Zhu G, et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2010; 8(1): 31-45.
83. Ho JC, Zhou T, Lai WH, et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany NY) 2011; 3(4): 380-390.
84. Liu GH, Barkho BZ, Ruiz S, et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011; 472(7342): 221-225.
85. Nissan X, Blondel S, Navarro C, et al. Unique Preservation of Neural Cells in Hutchinson- Gilford Progeria Syndrome Is Due to the Expression of the Neural-Specific miR-9 MicroRNA. Cell Rep 2012; 2(1): 1-9.
86. Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest 2009; 119(10): 3160-3171.
87. Huber I, Itzhaki I, Caspi O, et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. Faseb J 2007; 21(10): 2551-2563.
88. Ma Y, Jin J, Dong C, et al. High-efficiency siRNA-based gene knockdown in human embryonic stem cells. RNA 2010; 16(12): 2564-2569.
89. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zincfinger nucleases. Nat Biotechnol 2009; 27(9): 851-857.
90. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29(8): 731-734.
91. Carroll D. Zinc-finger nucleases: a panoramic view. Curr Gene Ther 2011; 11(1): 2-10.
92. Silva G, Poirot L, Galetto R, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011; 11(1): 11-27.
93. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1): 28-37.
94. Soldner F, Laganiere J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011; 146(2): 318-331.
95. Zou J, Maeder ML, Mali P, et al. Gene targeting of a diseaserelated gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5(1): 97-110.
96. Sasaki K, Inoue M, Shibata H, et al. Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved. Gene Ther 2005; 12(3): 203-210.
97. Dasen JS, Jessell TM. Hox networks and the origins of motor neuron diversity. Curr Top Dev Biol 2009; 88: 169-200.
98. Liss B, Roeper J. Individual dopamine midbrain neurons: functional diversity and flexibility in health and disease. Brain Res Rev 2008; 58(2): 314-321.
99. Mombaerts P, Wang F, Dulac C, et al. The molecular biology of olfactory perception. Cold Spring Harb Symp Quant Biol 1996; 61: 135-145.
100. Vaney DI, Sivyer B, Taylor WR. Direction selectivity in the retina: symmetry and asymmetry in structure and function. Nat Rev Neurosci 2012; 13(3): 194-208.
101. Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci 2011; 33: 409-440.
102. Placantonakis DG, Tomishima MJ, Lafaille F, et al. BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells 2009; 27(3): 521-532.
103. Lacoste A, Berenshteyn F, Brivanlou AH. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. Cell Stem Cell 2009; 5(3): 332-342.
104. Son EY, Ichida JK, Wainger BJ, et al. Conversion of Mouse and Human Fibroblasts into Functional Spinal Motor Neurons. Cell Stem Cell 2011; 9(3): 205-218.
105. Caiazzo M, Dell'Anno MT, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011; 476(7359): 224-227.
106. Marteyn A, Maury Y, Gauthier MM, et al. Mutant Human Embryonic Stem Cells Reveal Neurite and Synapse Formation Defects in Type 1 Myotonic Dystrophy. Cell Stem Cell 2011; 8(4): 434-444.
107. Boulting GL, Kiskinis E, Croft GF, et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011; 29(3): 279-286.
108. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136(5): 964-977.
109. Hotta A, Cheung AY, Farra N, et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 2009; 6(5): 370-376.
110. Cheung AY, Horvath LM, Grafodatskaya D, et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet 2010; 20(11): 2103-2115.
111. Baek KH, Zaslavsky A, Lynch RC, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459(7250): 1126-1130.
112. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010; 6(5): 407-411.